Market
Story
FDA Approves Johnson & Johnson's ($JNJ) Ketamine-Derived Spravato as Standalone Treatment for 21 Million US Adults with Treatment-Resistant Depression
Jan 21, 2025, 06:21 PM
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's ($JNJ) nasal spray, Spravato, for use as a standalone treatment for adults with treatment-resistant major depressive disorder (MDD). This approval marks Spravato as the first-ever monotherapy for this condition, which affects an estimated 21 million US adults who have not responded to at least two oral antidepressants. Previously, the ketamine-derived drug was approved for use in combination with oral antidepressants for treatment-resistant depression and for those with MDD experiencing suicidal thoughts. Spravato, which contains esketamine, has been administered to over 140,000 patients worldwide and has generated $780 million in sales during the first nine months of 2024. The approval is based on a phase four trial demonstrating that Spravato alone can improve depressive symptoms within 24 hours and maintain relief for at least one month.
View original story
Similar markets
Northeast • 25%
South • 25%
West • 25%
Midwest • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
West • 25%
South • 25%
Northeast • 25%
Midwest • 25%
0-10% • 25%
Over 30% • 25%
21-30% • 25%
11-20% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
Midwest • 25%
South • 25%
West • 25%
Northeast • 25%
5 to 10 • 25%
More than 15 • 25%
11 to 15 • 25%
Less than 5 • 25%
West Coast • 25%
Midwest • 25%
South • 25%
Northeast • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
North America • 25%
Africa • 25%
Asia • 25%
Europe • 25%